Level of depression and occurrence of cognitive changes in patients with multiple myeloma - a preliminary report
More details
Hide details
Instytut Psychologii, Uniwersytet Marii Curie-Skłodowskiej w Lublinie
Katedra i Klinika Hematoonkologii i Transplantacji Szpiku, Uniwersytet Medyczny w Lublinie
Submission date: 2021-10-29
Final revision date: 2022-05-20
Acceptance date: 2022-05-26
Publication date: 2022-07-31
Corresponding author
Magdalena Bury-Kamińska   

Instytut Psychologii, Uniwersytet Marii Curie-Skłodowskiej w Lublinie
JoMS 2022;48(1):461-475
The aim of the article is to study the changes in the level of cognitive and affective functioning in patients with multiple myeloma undergoing chemotherapy.

Material and methods:
Montreal Cognitive Assessment scale (MoCA) - screening method - was used to determine the general cognitive state of patients. The general level of depression and its characteristic symptoms were determined with the use of Depression Measurement Questionnaire.

Gathering first initial results of author’s own research – increasing the research sample could indicate an improved cognitive functioning in patients with multiple myeloma during chemotherapeutic treatment. Moreover, the research demonstrates a decrease in depression symptoms, i.e., self-blame and anxiety states, during chemotherapy.

The study requires further research owing to a small group of research participants (n=21), the presence of research data at the level of statistical tendency, and a need for a comparison with a group of healthy people (without a cancer diagnosis).

Bender, C.M., Sereika, S.M., Berga, S.L. i in. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. „Psycho‐Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer”, No. 15(5), s. 422–430.
Bury, M., Borkowska, A.R., Daniluk, B. (2014). Impact of chemotherapy on memory, attention and executive functions depending on the stages of treatment and the level of depression in female patients with cancer. „Acta Neuropsychologica”, No. 12(4).
Castellino, S.M., Ullrich, N.J., Whelen, M.J. i in. (2014). Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. „Journal of the National Cancer Institute”, 106 (8), 186.
Chojnacka-Szawłowska, G. (2012). Psychologiczne aspekty przewlekłych chorób somatycznych. Warszawa, Wydawnictwo Vizja Press & IT.
Cull, A., Hay, C., Love, S.B. i in. (1996). What do cancer patients mean when they complain of concentration and memory problems? „British Journal of Cancer”, No. 74(10), s. 1674.
de Walden-Gałuszko, K. (2014). Psychoonkologia w praktyce klinicznej. Warszawa: Wydawnictwo Lekarskie PZWL.
Debess, J., Riis, J.Ø., Engebjerg, M.C. i in. (2010). Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. „Breast Cancer Research and Treatment”, No. 121(1), s. 91–100.
Fallowfield, L. (1990). What is quality of life, London, Souvenir, s. 54–57.
Ferguson, R.J., McDonald, B.C., Saykin, A.J. i in. (2007). Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. „Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology”, No. 25(25), s. 3866–3870.
Hermelink K. (2011). Chemobrain? Zaburzenia poznawcze po chemioterapii. W: M. Dorfmüller, H. Dietzfelbinger (red.). Psychoonkologia. Diagnostyka – Metody terapeutyczne. Wrocław, Wydawnictwo Elsevier Urban & Partner, s. 71–73.
Hermelink, K. i in. (2010). Two different sides of ‘chemobrain’: determinants and nondeterminants of self‐perceived cognitive dysfunction in a prospective, randomized, multicenter study. „Psycho‐Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer”, No. 19(12), s. 1321–1328.
Jacobs, S.R. i in. (2007). Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. „Cancer”, No. 110(7), s. 1560–1567.
Jansen, C.E., Cooper, B.A., Dodd, M.J. (2011). A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients, „Supportive Care in Cancer”, No. 19(10), s. 1647–1656.
Jean-Pierre, P. (2010). Management of cancer-related cognitive dysfunction – conceptualization challenges and implications for clinical research and practice. „US Oncology”, No. 6(9).
Jones, D. i in. (2013). Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. „Cancer”, No. 119(23), s. 4188–4195.
Khalil, R.B. (2021). “Emotional Chemobrain”: A new concept for chemotherapy adverse drug effect?. „L’Encéphale”, No. 47(6), s. 613-615..
Łojek, E., Stańczak, J., Wójcik, A. (2015). Kwestionariusz do Pomiaru Depresji KPD. Podręcznik. Warszawa, Pracowania Testów Psychologicznych.
Mehlsen, M. i in. (2009). No indications of cognitive side‐effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. „Psycho‐Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer”, No. 18(3), s. 248–257.
Nowicki, A., Rządkowska, B. (2005). Depresja i lęk u chorych z nowotworami złośliwymi. „Współczesna Onkologia”, No. 9(9), s. 396–403.
Quesnel, C., Savard, J., Ivers, H. (2009). Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. „Breast Cancer Research and Treatment”, No. 116(1), s. 113–123.
Rolińska, A., Furmaga, O., Kwaśniewski, W. i in. (2011). Zaburzenia psychiczne w przebiegu choroby nowotworowej. „Current Problems of Psychiatry”, No. 12(4), s. 546–549.
Roman, S. i in. (2019). Cognition in Multiple Myeloma Patients. „Biology of Blood and Marrow Transplantation”, No. 25(3), s. 374–375.
Schagen, S.B. i in. (2006). Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. „Journal of the National Cancer Institute”, No. 98(23), s. 1742–1745.
Schagen, S.B. i in. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. „Cancer”, No. 85(3), s. 640–650.
Scherling, C.S., Smith, A. (2013). Opening up the window into “chemobrain”: a neuroimaging review. „Sensors”, No. 13(3), s. 3169–3203.
Silverman, D.H. i in. (2007). Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. „Breast Cancer Research and Treatment”, No. 103(3), s. 303–311.
Stępień, R., Wrońska, I. (2008). Lęk i depresja jako emocjonalne uwarunkowania możliwości funkcjonalnych kobiet po radykalnym leczeniu raka piersi. „Studia Medyczne”, nr 10, s. 31–35.
Talarowska, M. i in. (2011). Skala MOCA oraz MMSE w diagnozie łagodnych zaburzeń funkcji poznawczych. MOCA and MMSE in the diagnosis of Mild Cognitive Impairment. „Psychiatria i Psychoterapia”, nr 7(1), s. 13–20.
Tannock, I.F. i in. (2004). Cognitive impairment associated with chemotherapy for cancer: report of a workshop. „Journal of Clinical Oncology”, No. 22(11), s. 2233–2239.
Van Dam, F.S. i in. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. „Journal of the National Cancer Institute”, No. 90(3), s. 210–218.
Wefel, J.S. i in. (2004). ‘Chemobrain’in breast carcinoma? „Cancer”, No. 101(3), s. 466–475.
Whitney, K.A. i in. (2007). Is “chemobrain” a transient state? A prospective pilot study among persons with non-small cell lung cancer. „The Journal of Supportive Oncology”, No. 6(7), s. 313–321.
Journals System - logo
Scroll to top